CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of cancer.
  
  PURPOSE STATEMENT
  By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with HER2-altered solid tumors.
  
  LEARNING OBJECTIVES

  • Appreciate the spectrum and prevalence of HER2 alterations across various solid tumors and the means by which these contribute to tumor growth and proliferation.
  • Consider the scientific justification for the use of antibody-drug conjugates (ADCs) as a therapeutic approach for patients with HER2-altered solid tumors, and recall the mechanisms of antitumor activity of commercially available and investigational HER2-targeted agents.
  • Appraise available clinical research data with novel HER2-directed ADCs for patients with HER2-altered solid tumors, and consider the current and potential role of this approach in routine clinical care.
  • Recognize common and rare side effects associated with HER2-targeted ADCs employed in the care of patients with cancer, and use this information to develop supportive management plans.
  • Recollect ongoing clinical research attempting to further define the role of novel HER2-directed ADCs in treating various tumor types, and counsel appropriate patients regarding the potential benefits of trial participation.

  ACCREDITATION STATEMENT
  Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.
  
  CREDIT DESIGNATION STATEMENT
  This educational activity for 1.75 contact hours is provided by RTP during the period of June 2023 to June 2024.
  
  This activity is awarded 1.75 ANCC pharmacotherapeutic contact hours.
  
  ONCC/ILNA CERTIFICATION INFORMATION
  The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit https://www.researchtopractice.com/Meetings/ONS2023/PanTumorHER2/ILNA.
  
  ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.
  
  FOR SUCCESSFUL COMPLETION
  To receive credit, participants should read the learning objectives and faculty disclosures, watch the video, complete the post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ONS2023/PanTumorHER2/NCPD.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of NCPD activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Lyudmila A Bazhenova, MD
  Professor of Medicine
  Lung Cancer Unit Leader
  Director, Hematology and Oncology Fellowship Training Program
  UC San Diego Moores Cancer Center
  San Diego, California
  
  Consulting Agreements: AbbVie Inc, AnHeart Therapeutics, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, Elevation Oncology, Genentech, a member of the Roche Group, Gilead Sciences Inc, InterVenn Biosciences, Janssen Biotech Inc, Merck, Mirati Therapeutics Inc, NEUVOGEN Inc, Novocure Inc, Regeneron Pharmaceuticals Inc, Sanofi, Turning Point Therapeutics Inc; Data and Safety Monitoring Board/Committee: ORIC Pharmaceuticals (completed).
  
  Kelly EH Goodwin, MSN, RN, ANP-BC
  Thoracic Cancer Center
  Massachusetts General Hospital
  Boston, Massachusetts
  
  No relevant conflicts of interest to disclose.
  
  Virginia Kaklamani, MD, DSc
  Professor of Medicine
  Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment
  AB Alexander Distinguished Chair in Oncology
  Leader, Breast Oncology Program
  UT Health San Antonio MD Anderson Cancer Center
  San Antonio, Texas
  
  Consulting Agreements: AstraZeneca Pharmaceuticals LP, Gilead Sciences Inc, Puma Biotechnology Inc, TerSera Therapeutics LLC; Contracted Research: Eisai Inc; Data and Safety Monitoring Board/Committee: Bristol Myers Squibb; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Exact Sciences Corporation, Genentech, a member of the Roche Group, Gilead Sciences Inc, Novartis, Pfizer Inc, Seagen Inc.
  
  Caroline Kuhlman, MSN, APRN-BC
  Nurse Practitioner
  Tucker Gosnell Center for Gastrointestinal Cancers
  Massachusetts General Hospital
  Boston, Massachusetts
  
  Nonrelevant Financial Relationship: Clinical Care Options.
  
  Alexis N McKinney, MSN, AGNP-BC
  Adult-Gerontology Nurse Practitioner
  Mays Cancer Center
  UT Health San Antonio MD Anderson Cancer Center
  San Antonio, Texas
  
  No relevant conflicts of interest to disclose.
  
  Zev Wainberg, MD, MSc
  Co-Director, GI Oncology Program
  Director of Early Phase Clinical Research
  Jonsson Comprehensive Cancer Center
  UCLA School of Medicine
  Los Angeles, California
  
  Advisory Committee and Consulting Agreements: Arcus Biosciences, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Daiichi Sankyo Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Lilly, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc, Seagen Inc; Contracted Research: Arcus Biosciences, Bristol Myers Squibb, Plexxikon Inc; Data and Safety Monitoring Board/Committee: Daiichi Sankyo Inc, Pfizer Inc.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop NCPD activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.
  
  RTP NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Daiichi Sankyo Inc.
  
  Release date: June 2023
  Expiration date: June 2024
  
  There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.